NEUROCRINE BIOSCIENCES INC
NBIXUS売上高
$2.9B
百万USD
営業利益
$619M
百万USD
純利益
$479M
百万USD
ROE
14.7%
最新FY
EPS
$4.67
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $237M | $32M | $0.33 |
| FY2021 | Q2 | $289M | $42M | $0.43 |
| FY2021 | Q3 | $296M | $23M | $0.23 |
| FY2021 | FY | $1.1B | $90M | $0.92 |
| FY2022 | Q1 | $311M | $14M | $0.14 |
| FY2022 | Q2 | $378M | $-17M | $-0.18 |
| FY2022 | Q3 | $388M | $69M | $0.69 |
| FY2022 | FY | $1.5B | $155M | $1.56 |
| FY2023 | Q1 | $420M | $-77M | $-0.79 |
| FY2023 | Q2 | $453M | $96M | $0.95 |
| FY2023 | Q3 | $499M | $83M | $0.82 |
| FY2023 | FY | $1.9B | $250M | $2.47 |
| FY2024 | Q1 | $515M | $43M | $0.42 |
| FY2024 | Q2 | $590M | $65M | $0.63 |
| FY2024 | Q3 | $622M | $130M | $1.24 |
| FY2024 | FY | $2.4B | $341M | $3.29 |
| FY2025 | Q1 | $573M | $8M | $0.08 |
| FY2025 | Q2 | $688M | $108M | $1.06 |
| FY2025 | Q3 | $795M | $210M | $2.04 |
| FY2025 | FY | $2.9B | $479M | $4.67 |
| FY2026 | Q1 | $815M | $198M | $1.91 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $451M | $788M | $1.0B | $1.1B | $1.5B | $1.9B | $2.4B | $2.9B |
| 営業利益 | $-147M | $-131M | $37M | $72M | $163M | $103M | $249M | $251M | $571M | $619M |
| 純利益 | $-141M | $-143M | $21M | $37M | $407M | $90M | $155M | $250M | $341M | $479M |
| 総資産 | $365M | $818M | $993M | $1.3B | $1.7B | $2.1B | $2.4B | $3.3B | $3.7B | $4.6B |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $315M | $372M | $481M | $637M | $1.1B | $1.4B | $1.7B | $2.2B | $2.6B | $3.3B |
| 営業CF | - | - | $101M | $152M | $229M | $257M | $339M | $390M | $595M | $783M |
| EPS | $-1.63 | $-1.62 | $0.22 | $0.39 | $4.16 | $0.92 | $1.56 | $2.47 | $3.29 | $4.67 |
| BPS | $3.61 | $4.17 | $5.29 | $6.90 | $11.99 | $14.43 | $17.68 | $22.43 | $25.97 | $32.41 |
| ROE | -44.8% | -38.3% | 4.4% | 5.8% | 36.2% | 6.5% | 9.0% | 11.2% | 13.2% | 14.7% |